Back to top
more

InMode (INMD)

(Delayed Data from NSDQ)

$16.50 USD

16.50
1,402,980

+0.34 (2.10%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $16.47 -0.03 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

InMode (INMD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

InMode (INMD) closed at $39.49 in the latest trading session, marking a +1.02% move from the prior day.

Here's Why Investors Should Hold Humana (HUM) in Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.

Cigna (CI) Eases Care Delivery With Prior Authorization Removal

by Zacks Equity Research

Cigna's (CI) branch, Cigna Healthcare, lifts the prior authorization requirement on 600-plus medical services, thereby easing administrative burdens and making way for simplified care delivery.

InMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.

InMode (INMD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

InMode (INMD) delivered earnings and revenue surprises of 2.86% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging InMode (INMD) This Year?

by Zacks Equity Research

Here is how InMode (INMD) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

InMode (INMD) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.

InMode (INMD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, InMode (INMD) closed at $45.21, marking a -0.09% move from the previous day.

InMode (INMD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

InMode (INMD) closed at $46.04 in the latest trading session, marking a +0.55% move from the prior day.

Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

InMode (INMD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, InMode (INMD) closed at $45.19, marking a -0.07% move from the previous day.

biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ethan Feller headshot

3 Top-Tier Stocks Trading at Historical Discounts

by Ethan Feller

Hard to go wrong buying high quality stocks at a discount

Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.

Is InMode (INMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how InMode (INMD) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare

by Zacks Equity Research

InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.

Indrajit Bandyopadhyay headshot

Solid Earnings Fuel Potential Bull Market in Medical Devices

by Indrajit Bandyopadhyay

CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

Wall Street Analysts Think InMode (INMD) Could Surge 45.95%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 46% in InMode (INMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

InMode (INMD) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe InMode (INMD) Could Rally 33.66%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 33.7% upside potential for InMode (INMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

InMode (INMD) Soars 12.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

InMode (INMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.